Gyre Therapeutics

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$26,771
$22,058
$27,872
$25,488
Gross Profit
25,620
21,164
26,695
24,530
EBITDA
2,813
2,808
1,243
4,233
EBIT
2,172
2,273
772
3,779
Net Income
442
2,698
-99
5,004
Net Change In Cash
26,771
22,058
27,872
25,488
Free Cash Flow
1,832
-251
-2,693
1,033
Cash
36,491
15,045
11,813
15,866
Basic Shares
102,701
101,970
102,293
102,640

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$105,757
$113,450
$102,290
$7,338
Gross Profit
101,873
108,814
97,497
-42
EBITDA
17,817
20,327
10,332
-87,604
EBIT
16,229
19,213
9,203
-87,894
Net Income
12,085
-92,933
2,302
-87,933
Net Change In Cash
105,757
113,450
102,290
7,338
Free Cash Flow
-5,956
17,306
-38,094
-84,594
Cash
11,813
33,509
25,175
44,347
Basic Shares
102,293
65,831
75,686
30,640

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
$0.002
2025-03-31
$0.004
2024-12-31
-$0.001